Featured Solutions

  1. Two Regulatory Pathways — One Expert Partner 4/25/2025

    Whether you’re pursuing an IND submission in the U.S. or a CTA in Canada and Europe, our integrated solutions model provides comprehensive regulatory support at every drug development stage.

  2. Drug-Drug Interaction Clinical Trials 3/19/2025

    We specialize in DDI studies, including stand-alone and 'cocktail' designs, assessing multiple CYP enzymes or transporters in single studies, from simple crossovers to complex adaptive trials.

  3. Renal And Hepatic Impaired Studies 11/20/2024

    Altasciences has successfully designed, conducted, analyzed, and reported numerous clinical trials focused on renal and hepatic impairment across a wide range of therapeutic areas.

  4. Metabolic Disorders 10/8/2024

    Altasciences has over 25 years of experience in metabolic diseases and supports every stage of the development process, from discovery to clinical trials — and beyond.

  5. Flow Cytometry And PBMC Isolation — Powerful Tools For Your Clinical Trials 8/20/2024

    Did you know? Altasciences’ clinical facilities are integrated with state-of-the-art flow cytometry laboratories. With our deep expertise in regulated cellular analysis, our team ensures that every step — from sample collection and processing to transport and analysis — is optimized for precision and speed.

  6. Clinical Trial Site Selection And Management 7/25/2024

    Our network of 150+ active clinical trial sites allows us to identify potential partners that align with your therapeutic area, geographic preference, and specialty population requirements.

  7. Clinical Pharmacology Studies For NDA Filing 6/18/2024

    Need help with inclusion/exclusion criteria for your Phase 2/3 protocol or an unexpected FDA post-marketing amendment? Altasciences offers reliable solutions with a quick start-up.

  8. Human Abuse Potential 4/17/2024

    With over 60 HAP studies successfully conducted in the last decade, Altasciences has experience in diverse areas such as for stimulants, opioids, and sedative-hypnotics.

  9. Comprehensive Services CNS Drug Development 4/9/2024

    Our approach is designed to optimize efficiency and accelerate timelines, resulting in up to 40% time savings throughout the early phases of your drug development journey.

  10. Your Top Partner For Ophthalmic Drug Development 4/9/2024

    As a leading partner in ocular therapy, Altasciences is at the forefront of ophthalmic drug development. Our integrated CRO/CDMO solutions can support your program from lead candidate selection to market. You will benefit from working with a single partner as your product advances through each phase of drug development—from prototype formulation through preclinical testing, to early phase clinical trials, and manufacturing. This could mean up to 40% in time savings.